Vaxcyte (PCVX) is a clinical-stage vaccine innovation company focused on developing next-generation vaccines to protect people from serious bacterial infectious diseases. While Vaxcyte is still a clinical-stage company, Wall Street seems highly optimistic about PCVX stock, rating it as a consensus “Strong Buy” and forecasting potential upside of 76% from current levels based on the average price target of $109.
Vaxcyte is even attracting long-term growth investors' interest. This small-cap biotech is up 35% so far this year, outperforming many Big Tech names.
